<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674505</url>
  </required_header>
  <id_info>
    <org_study_id>G070189/S002</org_study_id>
    <nct_id>NCT00674505</nct_id>
  </id_info>
  <brief_title>Safety &amp; Performance Study of Lumen Biomedical's FiberNet Distal Protection System for the Treatment of Renal Artery Stenosis</brief_title>
  <acronym>FORTRESS</acronym>
  <official_title>FiberNet Renal Artery Embolic Protection Study: A Prospective, Single-arm Feasibility Trial of Renal Artery Distal Protection Using the Lumen Biomedical FiberNet Embolic Protection System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVA Physicians</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lumen Biomedical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prairie Education and Research Cooperative</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VIVA Physicians</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the procedural safety and filter efficiency of the FiberNet® Embolic Protection
      System when used in conjunction with the Boston Scientific Express SD Stent System for
      primary stenting of ostial atherosclerotic renal lesions in patients with atherosclerotic
      renal artery stenosis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurable amount of macro/micro atheroma particle captured by the FiberNet EPS as adjudicated by core lab analysis.</measure>
    <time_frame>Various secondary endpoints evaluated at 30 days and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression to temporary/permanent renal replacement therapy and Analysis of debris captured by the FiberNet® Embolic Protection System</measure>
    <time_frame>most at 30 days and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Renal Stenting in the Treatment of Pts w/a High Grade Ostial Atherosclerotic Renal Lesion(s).</condition>
  <arm_group>
    <arm_group_label>Treatment, Open label, Single Group Assignment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lumen Biomedical FiberNet Embolic Protection System</intervention_name>
    <description>to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).</description>
    <arm_group_label>Treatment, Open label, Single Group Assignment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 and ≤ 85 years.

          2. Subject or subject's legal representative have been informed of the nature of the
             study, agrees to participate and has signed an IRB approved consent form.

          3. Subject understands the duration of the study and it's follow up visit requirements.

          4. Unilateral or bilateral atherosclerotic de novo renal artery stenosis (RAS) associated
             with any or all of the following:

               1. SBP &gt;140 despite ≥3 anti-hypertensive medications

               2. Estimated Glomerular Filtration Rate (eGFR) ≥30-≤70 cc/min calculated using the
                  Modified Diet in Renal Disease (MDRD) formula

               3. Recurrent episodes of decompensated heart failure

               4. Recurrent episodes of &quot;flash&quot; pulmonary edema

        Angiographic Inclusion Criteria

          1. ≥70% &lt;100% renal artery stenosis (by visual estimate) involving unilateral, bilateral
             renal arteries or solitary renal artery.

          2. Renal pole-to-pole length &gt;7cm.

          3. Lesion ≤15 mm from the aorto-ostial junction.

          4. Renal artery reference lumen diameter ≥3.5 - ≤7 mm for FiberNet placement.

        Exclusion Criteria:

        Clinical Exclusion Criteria

          1. Estimated life expectancy &lt;12 months.

          2. Estimated Glomerular Filtration Rate (eGFR) &lt;30 cc/min.

          3. Renal pole-to-pole length &lt;7cm on side of diseased kidney.

          4. No history of transplanted kidneys or polycystic kidney disease.

          5. Uncontrolled hypercoagulability.

          6. Known allergies or sensitivities to heparin, aspirin, other
             anti-coagulant/antiplatelet therapies, nitinol and stainless steel.

          7. Known allergy to contrast media that cannot adequately be pre-medicated prior to study
             procedure.

          8. Patient refuses possible temporary or permanent hemodialysis.

          9. Refuses possible surgery for repair of access site or renal artery.

         10. Known severe coronary or carotid disease likely to require surgical treatment after
             enrollment or during follow-up period.

         11. Uncompensated congestive heart failure.

         12. Current enrollment in any investigational study wherein patient participation has not
             been completed.

         13. Cardiovascular surgical or cardiovascular interventional procedures (including, but
             not limited to, aortic, renal, cardiac, carotid, femoro-popliteal, and below the knee)
             within 30 days prior to enrollment in this study.

         14. Planned or predicted cardiovascular surgical or interventional procedures outside of
             the affected renal artery (including, but not limited to, aortic, renal, cardiac,
             carotid, contralateral femoro-popliteal, and contralateral below the knee) within 30
             days after entry into this study and prior to completion of the 30 day follow-up.

         15. Pregnancy, breast-feeding or plans to become pregnant in female of child bearing
             potential.

         16. Any patient who in the opinion of the investigator would not be a good candidate for
             enrollment.

        Angiographic Exclusion Criteria

          1. Early bifurcation of the main renal artery preventing complete embolic protection of
             the kidney with the FiberNet.

          2. Fibromuscular Dysplasia.

          3. Presence of thrombus at the lesion site.

          4. Non-ostial atherosclerosis (lesion &gt;15mm from the renal ostium).

          5. Subintimal guidewire placement resulting in dissection of the renal artery or aorta,
             or perforation of the renal artery or aorta prior to deployment of the device.

          6. Severe calcification likely to prevent the passage of the device. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VIVA Physicians Inc.</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <last_update_submitted>February 16, 2010</last_update_submitted>
  <last_update_submitted_qc>February 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>John R. Laird, MD</name_title>
    <organization>University of California, Davis</organization>
  </responsible_party>
  <pending_results>
    <submitted>August 24, 2015</submitted>
    <returned>September 22, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

